In a world where there are 350 million rare disease patients, we recognize that we have to do something. In a field that addresses over 7,000 rare diseases, we realize that we have to start somewhere. In an industry that has less than 5% of approved treatments, we are here to be the ones who make bold progress.

CENTOGENE is on a mission to enable the cure of 100 rare diseases in 10 years. At the core of everything we do? Data. Leveraging a multi-pronged method to diagnose, understand, and treat rare diseases, CENTOGENE is the leading data-driven rare disease company.

Founded in 2006 with focus on rare, metabolic, and neurodegenerative – addressing the complete patient journey

Headquarters in Rostock, Germany, with other locations in Boston, MA, Berlin, Germany, and Rotkreuz, Switzerland

Rare disease-centric Biodatabank with >800,000 individuals

CENTOGENE’s diagnostic footprint reaches far beyond our German roots. Having diagnosed over 2,500 rare diseases across 100 countries alongside a network of over 30,000 physicians, we have been spearheading revolutionary diagnostic solutions since we were founded in 2006. We have the broadest diagnostic testing portfolio for rare diseases, covering over 19,000 genes using over 10,000 different tests. Together, we can revolutionize the early detection of rare diseases.

Since our founding, CENTOGENE has generated data-driven insights from our diagnostic business. Through our in-house research, we have discovered unique links between genetic diseases and their downstream effects using myriad ‘omic’ technologies. Our experts have contributed to over 200 peer reviewed publications. With our technology and expertise, we can help elucidate disease pathways, identify drug targets, and screen candidate drugs.

We leverage our rare disease-centric Bio/Databank to revolutionize orphan drug development, working alongside over 30 pharmaceutical partners. CENTOGENE is currently pursuing research on three priority diseases – Gaucher disease, Niemann-Pick type C, and genetic Parkinson’s. Our mission: to enable the cure of 100 rare diseases in 10 years.